The initiatives are expected to benefit industry players. "It is expected that the approved pharmaceutical products are safer,
following safety and ethical norms," Dhanoa explains. The center would also ensure that approvals for products are obtained
more quickly or are manufactured in such a way as to decrease potential patient and safety problems.
"In a competitive environment, it is crucial for pharmaceutical products to reach the market in a short span of time. Hence,
the regulatory center is expected to explore the shortest route and timeframe to put these products on the market, and support
the lifecycle management of the products. This will prove to be advantageous for start-up and local firms in Taiwan," says
In addition, the approval process for new drug and generic-drug manufacturing and marketing applications would include a review
of the manufacturer's compliance with GMP as set by Taiwan's FDA. Based on standard operating procedures and guidelines, the
regulatory center would determine whether the firm has the necessary facilities, equipment, and skills to manufacture the
new drug for which it has applied for approval. Decisions regarding compliance with regulations are likely to be based on
inspection of the facilities and sample analyses, which are expected to affect foreign firms entering the market.
The impact of the center's establishment can be viewed from both short- and long-term perspectives according to Lee. From
a short-term perspective, one can expect an increase in cooperation and communication in academic research on pharmaceutical
regulation that would promote collaboration between local regulatory agencies as well as foreign regulatory agencies and academic
institutions. Such exchanges could result in a convergence of approaches to pharmaceutical regulations. Additionally, the
Taiwan pharmaceutical industry could potentially see a shift in regulatory agencies taking a more science-based approach to
the assessment of safety, efficacy, quality, and performance of regulated products.
Looking forward, this development may well position the Taiwanese regulatory agency as a forward-looking agency, particularly
in North Asia. "As a platform to promote regulatory science within the pharmaceutical industry, the center would show the
local region as well as the surrounding regions its aim to improve the overall efficiency of the industry. The movement would
promote regulatory science through local and regional collaboration," Kao says.
—Jane Wan is a freelance writer based in Singapore